Next‐Generation Preclinical Functional Testing Models in Cancer Precision Medicine: CTC‐Derived Organoids

Abstract

Basic and clinical cancer research requires tumor models that consistently recapitulate the characteristics of prima tumors. As ex vivo 3D cultures of patient tumor cells, patient‐derived tumor organoids possess the biological properties of primary tumors and are therefore excellent preclinical models for cancer research. Patient‐derived organoids can be established using primary tumor tissues, peripheral blood, pleural fluid, ascites, and other samples containing tumor cells. Circulating tumor cells acquired by non‐invasive sampling feature dynamic circulation and high heterogeneity. Circulating tumor cell‐derived organoids are prospective tools for the dynamic monitoring of tumor mutation evolution profiles because they reflect the heterogeneity of the original tumors to a certain extent. This review discusses the advantages and applications of patient‐derived organoids. Meanwhile, this work highlights the biological functions of circulating tumor cells, the latest advancement in research of circulating tumor cell‐derived organoids, and potential application and challenges of this technology.

Advances in Precision Medicine Approaches for Colorectal Cancer: From Molecular Profiling to Targeted Therapies

“…As the field advances, ensuring the reproducibility and reliability of identified biomarkers across diverse patient cohorts and clinical settings remains a priority. , Additionally, the integration of molecular profiling into routine clinical practice requires the development of user-friendly, cost-effective, and widely accessible diagnostic tools. Bridging the gap between cutting-edge research findings and routine patient care will be essential for the successful implementation of precision medicine strategies in colorectal cancer. , …”

“…Bridging the gap between cuttingedge research findings and routine patient care will be essential for the successful implementation of precision medicine strategies in colorectal cancer. 242,243 Moreover, the ethical considerations surrounding the use of genomic and proteomic data in clinical decision-making must be addressed. Safeguarding patient privacy, ensuring informed consent, and addressing potential biases in data interpretation are critical aspects that demand ongoing attention.…”

Pancreatic cancer environment: from patient-derived models to single-cell omics

“…The organoid application addresses the limitation caused by the reduced number of CTCs, enabling their expansion to a certain extent. 39 Moreover, it amplifies the genetic heterogeneity within CTCs, thus facilitating enhanced research capabilities. 40 Furthermore, peripheral blood CTCs’ stem-like properties retain the observed proliferative capacity of the primary tumor and form organoids to facilitate comprehensive analysis of tumor metastasis and drug resistance.…”

SOAT1 in gallbladder cancer: Clinicopathological significance and avasimibe therapeutics

“…Its practical application demonstrates advantages unparalleled by traditional therapies, such as reduced organ damage, lower side effects, reduced likelihood of developing drug resistance, greater efficacy in eradicating residual tumor cells, long-term effectiveness, and prevention of recurrence. [18][19][20][21] However, immunotherapy still carries inherent limitations. Challenges such as specificity issues, low immunogenicity, inadequate delivery efficiency, and off-target side effects remain prominent.…”